ENSC Ensysce Biosciences
- 0.5842
- +0.0375+6.86%
- 0.6102
- +0.0260+4.45%
Ensysce Biosciences News
Ensysce Biosciences' Presentation From the Noble Capital Markets Emerging Growth Virtual Healthcare Equity Conference Published
Noble Capital Markets ("Noble") is a research-driven investment bank that has supported small and microcap companies since 1984.
Ensysce Biosciences Reports Q4 Results
Ensysce Biosciences Q4 EPS $(1.13) Misses $(0.87) Estimate, Sales $515.03K Beat $390.00K Estimate
Ensysce Biosciences (NASDAQ:ENSC) reported quarterly losses of $(1.13) per share which missed the analyst consensus estimate of $(0.87) by 29.89 percent. This is a 93.8 percent increase over losses of
Ensysce Biosciences Reports Fourth Quarter and Full Year 2023 Financial Results
Ensysce Biosciences, Inc. ("Ensysce" or the "Company") (NASDAQ:ENSC), a clinical-stage company applying transformative chemistry to improve prescription drug safety, today reported financial results for the fourth quarter and full year of 2023.
Ensysce Biosciences Announces The Co May Continue Its Listing On The Nasdaq Capital Market Tier With An Extension To May 13, 2024 In Order To Demonstrate Compliance With The Equity Requirement In Listing Rule 5550(b)(1)
Ensysce Biosciences, Inc. (the "Company") (NASDAQ:ENSC), a clinical-stage company applying transformative chemistry to improve prescription drug safety, today announced that it has received notice fro
Ensysce Receives FDA Guidance on Opioid With Overdose Protection
Ensysce Biosciences Receives FDA Guidance For PF614-MPAR Program
The meeting focused on the Company's non-clinical program for the combination product that is designed for the treatment of severe pain. The FDA provided helpful feedback and advice on non-clinical st
Ensysce Biosciences Announces Successful Meeting With FDA for PF614-MPAR, a Next Generation Opioid With Overdose Protection
Ensysce Biosciences, Inc. (NASDAQ:ENSC) ("Ensysce" or the "Company"), a clinical-stage company applying transformative chemistry to improve prescription drug safety, is providing an update following its recent meeting with the Food and Drug Administration (FDA) regarding its second product, a 'Next Generation' opioid analgesic with overdose protection, PF614-MPAR.
Ensysce Biosciences Reports Promising PF614 Study Results
Ensysce Biosciences Secures Funding and Expands Shareholder Value
Ensysce Biosciences Exercises Rights to Buy Shares at a Lower Price
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
GainersKalVista Pharma (NASDAQ:KALV) stock moved upwards by 31.5% to $21.1 during Tuesday's pre-market session. The market value of their outstanding shares is at $729.1 million. Jin Medical Internati
Ensysce Biosciences, Inc. Announces Exercise of Warrants for $4.7 Million Gross Proceeds
SAN DIEGO, CA / ACCESSWIRE / February 13, 2024 / Ensysce Biosciences, Inc. (NASDAQ:ENSC) (the "Company"), a clinical-stage biotech company applying transformative chemistry to improve prescription dru
TENX, PBM and PRSO Among Pre-market Losers
Ensysce Biosciences Selected to Present at American Association of Pain Medicine Annual Conference
Ensysce Biosciences, Inc. (NASDAQ:ENSC) today announced they have been selected to present one of the top 12 best Flash Talks in the Trailblazer Session at the 2024 American Association of Pain Medicine (AAPM) Meeting on March 9th.
Conmed, Relmada Therapeutics Among Healthcare Movers
IFBD, BFRG and GHSI Among Pre-market Losers
12 Health Care Stocks Moving In Wednesday's After-Market Session
GainersTransCode Therapeutics (NASDAQ:RNAZ) shares moved upwards by 17.2% to $0.81 during Wednesday's after-market session. Align Tech (NASDAQ:ALGN) shares increased by 13.29% to $302.86. The company'
Theratechnologies, DocGo Among Healthcare Movers
Market-Moving News for January 31st
ENSC: 92% | Ensysce Biosciences Reports Completion Of A Constructive End Of Phase 2 Meeting With FDA Regarding Its Lead 'Next Generation' Analgesic, PF614; Phase 3 Program Expected To Begin Enrollment
Analysis
Price Target
No Data
